Overview

Price chart · mood · technical indicators

DRTS

Alpha Tau Medical Ltdstock Healthcare

Biotechnology

$10.58276.51%Current Market Mood:Strong Bullish

Market Mood

Price Range (1Y)

$2.81$11.62

Current: $10.58

Idea: EMA

1Y Return

+122.7%

Sharpe 3Y

0.81

Market Comparison

vs Healthcare Sector & Biotechnology Industry

DRTS

+276.51%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-0.670.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$976.4MSmall cap

Wall Street coverage

$13.80median target· current $2.60 (+431.8%)5 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 12.59
P/S (TTM): —
EV/EBITDA: -4.77

Profitability & growth

ROE (TTM): -90.5%
Operating margin: 0.0%
Revenue growth YoY: 0.0%
Dividend yield: —
Beta: 1.12

Last earnings

May 18, 2026 · Estimate $-0.12 · Reported $-0.26

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Alpha Tau Medical Ltd

Company profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha DaRT) for the treatment of solid cancer in Israel and the United States. The company is headquartered in Jerusalem, Israel.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: KIRYAT HAMADA ST. 5, JERUSALEM, ISRAEL
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$976.4M

Shares outstanding$90.3M

52W high$11.62

52W low$2.82

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

Overview

DRTS

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

[144] Alpha Tau Medical Ltd. SEC Filing

H.C. Wainwright Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Maintains Target Price $15

Alpha Tau (DRTS) lands Tolmar partnership with $20M equity and milestones

New prostate cancer radiation option backed by $35M Alpha Tau–Tolmar deal

Alpha Tau and Tolmar Announce Strategic Collaboration to

Number of shareholders of Alpha Tau Medical Ltd. – NASDAQ:DRTSW

Barclays Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Maintains Target Price $15

Alpha Tau Medical Reports Data Showing Alpha DaRT Increases Overall Survival for Patients With Pancreatic Cancer

Alpha Tau Announces Strong Overall Survival Results from

Alpha Tau trial links one-time pancreatic treatment to 11‑month survival

Alpha Tau Medical (Nasdaq:DRTS) - Stock Analysis

Barclays Initiates Alpha Tau Medical With Overweight Rating, $15 Price Target

DRTS Initiated Coverage by Barclays - Rating Overweight with Tar

DRTS: Key cancer trials advance with pivotal data expected in 2026; strong financial position maintained

Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST)

DRTS Technical Analysis | Trend, Signals & Chart Patterns | ALPHA TAU MEDICAL LTD (NASDAQ:DRTS)

DRTSW Stock Price, Quote & Chart | ALPHA TAU MEDICAL LTD -27 (NASDAQ:DRTSW)

DRTS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15

H.C. Wainwright reiterates Buy on Alpha Tau stock, $15 target

Alpha Tau Medical (NASDAQ: DRTS) sets 2026 shareholder vote on pay, board and auditors

About Alpha Tau Medical Ltd

Classification

Company profile

DRTS

Market Comparison

DRTS Market Analysis

Overview

DRTS

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

[144] Alpha Tau Medical Ltd. SEC Filing

H.C. Wainwright Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Maintains Target Price $15

Alpha Tau (DRTS) lands Tolmar partnership with $20M equity and milestones

New prostate cancer radiation option backed by $35M Alpha Tau–Tolmar deal

Alpha Tau and Tolmar Announce Strategic Collaboration to

Number of shareholders of Alpha Tau Medical Ltd. – NASDAQ:DRTSW

Barclays Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Maintains Target Price $15

Alpha Tau Medical Reports Data Showing Alpha DaRT Increases Overall Survival for Patients With Pancreatic Cancer

Alpha Tau Announces Strong Overall Survival Results from

Alpha Tau trial links one-time pancreatic treatment to 11‑month survival

Alpha Tau Medical (Nasdaq:DRTS) - Stock Analysis

Barclays Initiates Alpha Tau Medical With Overweight Rating, $15 Price Target

DRTS Initiated Coverage by Barclays - Rating Overweight with Tar

DRTS: Key cancer trials advance with pivotal data expected in 2026; strong financial position maintained

Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST)

DRTS Technical Analysis | Trend, Signals & Chart Patterns | ALPHA TAU MEDICAL LTD (NASDAQ:DRTS)

DRTSW Stock Price, Quote & Chart | ALPHA TAU MEDICAL LTD -27 (NASDAQ:DRTSW)

DRTS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15

H.C. Wainwright reiterates Buy on Alpha Tau stock, $15 target

Alpha Tau Medical (NASDAQ: DRTS) sets 2026 shareholder vote on pay, board and auditors

About Alpha Tau Medical Ltd

Classification

Company profile

DRTS

Market Comparison